Clinical Trial Results:
An Open-Label, Single-Dose Study to Assess the Safety of 500- mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive
Summary
|
|
EudraCT number |
2015-001226-42 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
12 Mar 2010
|
Results information
|
|
Results version number |
v1 |
This version publication date |
06 Jul 2016
|
First version publication date |
05 Aug 2015
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
MEBENDAZOLGAI3002
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01173562 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Johnson & Johnson Pharmaceutical Research & Development
|
||
Sponsor organisation address |
Turnhoutseweg 30, 2340 Beerse, Belgium,
|
||
Public contact |
Clinical Registry Group-JB BV, Johnson & Johnson Pharmaceutical Research & Development, ClinicalTrialsEU@its.jnj.com
|
||
Scientific contact |
Clinical Registry Group-JB BV, Johnson & Johnson Pharmaceutical Research & Development, ClinicalTrialsEU@its.jnj.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
12 Mar 2010
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
12 Mar 2010
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the safety and tolerability of a mebendazole 500-mg chewable tablet formulation in a pediatric population (children 2 to 10 years of age, inclusive).
|
||
Protection of trial subjects |
The safety assessments included Adverse events, vital sign measurements (axillary temperature, pulse, respiratory rate, and Blood Pressure [BP]) and Physical examinations (including height and body weight).
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
24 Feb 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Tanzania, United Republic of: 396
|
||
Worldwide total number of subjects |
396
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
396
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||
Recruitment
|
|||||||||||
Recruitment details |
- | ||||||||||
Pre-assignment
|
|||||||||||
Screening details |
A total of 396 participants were enrolled and treated with a Single dose of Mebendazole 500 mg. | ||||||||||
Period 1
|
|||||||||||
Period 1 title |
Open Label (overall period)
|
||||||||||
Is this the baseline period? |
Yes | ||||||||||
Allocation method |
Non-randomised - controlled
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Arms
|
|||||||||||
Arm title
|
Mebendazole 500 mg | ||||||||||
Arm description |
Participants received a single dose of Mebendazole 500-mg chewable tablet on Day 1. | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
MEBENDAZOLE
|
||||||||||
Investigational medicinal product code |
SUB08660MIG
|
||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Chewable tablet
|
||||||||||
Routes of administration |
Oral use
|
||||||||||
Dosage and administration details |
A single Dose of Mebendazole Chewable tablet 500 mg administered.
|
||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Mebendazole 500 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received a single dose of Mebendazole 500-mg chewable tablet on Day 1. | ||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Mebendazole 500 mg
|
||
Reporting group description |
Participants received a single dose of Mebendazole 500-mg chewable tablet on Day 1. | ||
Subject analysis set title |
Safety Analysis Set (SAS)
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
Safety Analysis Set (SAS) includes Participants who received a single dose of mebendazole 500 mg and contributed any safety data after the start of study treatment.
|
|
|||||||||||||
End point title |
Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) [1] | ||||||||||||
End point description |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Up to 3 days after study drug administration
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No inferential statistics was planned to be performed on this primary endpoint. |
|||||||||||||
|
|||||||||||||
Notes [2] - SAS |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Number of Participants with Abnormal Vital Signs | ||||||||
End point description |
Vital signs included assessment of axillary temperature, pulse, respiratory rate, and BP on Day 1 and Day 3
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Up to 3 Days after study drug administration
|
||||||||
|
|||||||||
Notes [3] - SAS |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Number of Participants with Abnormal Physical Examinations at End-of-Study (EOS) | ||||||||
End point description |
Physical examination included evaluation of body organs (Skin, Eyes, Ears, Nose, Throat, Head, Neck, Thyroid, Heart, Lung, Chest (include Breasts), Abdomen, Genitalia, Anorectal, Lymph nodes, Musculoskeletal, Neurological, Other)
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Up to 3 Days after study drug administration
|
||||||||
|
|||||||||
Notes [4] - SAS |
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Up to 3 days after study drug administration
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
12.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Mebendazole 500 mg
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants received a single dose of Mebendazole 500-mg chewable tablet on Day 1. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
16 Oct 2009 |
The overall reason for the amendment was to change in the protocol title to accurately reflect that medbendazole 500 mg is a new formulation of an existing drug (VERMOX®), but not a new drug, Replacement of oral temperature with axillary temperature, to clarify regarding stool samples, to address IRB concern on adverse events, Removal of reference to blood plasma and urine samples. |
||
21 Jan 2010 |
The overall reason for the amendment was to modify wording of exclusion criteria and removal of reference to mebendazole as VERMOX. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |